Skip to content

One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance

One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07336290
Enrollment
10000
Registered
2026-01-13
Start date
2010-01-01
Completion date
2030-12-30
Last updated
2026-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Cardiomyopathy (HCM)

Keywords

cardiac magnetic resonance, diagnosis, risk stratificaiton, artificial intelligence, personalized prognosis

Brief summary

This is a multi-center, observational study aiming to establish a precision diagnosis scheme and multi-dimensional risk prediction models for Hypertrophic Cardiomyopathy (HCM). The study plans to enroll 10000 adult HCM patients. It will integrate genetic testing, advanced cardiac imaging (echocardiography and cardiac magnetic resonance), and biomarker analysis to develop early diagnosis, differential diagnosis, and new risk prediction models for sudden cardiac death (SCD) and heart failure in HCM patients. Participants will undergo baseline assessments and be followed up every six months for up to 3 years to track clinical outcomes. This study is non-interventional and does not involve any investigational drugs or devices.

Interventions

None listed

Sponsors

Minjie Lu
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

A maximal left ventricular wall thickness of ≥ 12 mm in any segment at end-diastole, as measured by echocardiography or Cardiac Magnetic Resonance (CMR)

Exclusion criteria

* Presence of any contraindication to CMR examination. * Unwillingness to participate in the study or to provide informed consent.

Design outcomes

Primary

MeasureTime frame
Number of participants with sudden cardiac death5-year

Secondary

MeasureTime frame
Number of participants with all-cause mortality5-year
Number of participants with atrial fibrillation5-year
Number of participants with heart failure hospitalization5-year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026